Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
1 clinical trials · Condition
◉ Watch Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
| Record | Firm | Date |
|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma (NCT07583810) | City of Hope Medical Center | 2026-12-16 |
Track Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.